Deadline: 29 September 2020

Next deadlines:

17 March 2021

Topic:

Topic 1: Returning clinical trial data to study participants within a GDPR compliant and approved ethical framework
Topic 2: Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance
Topic 3: A platform for accelerating biomarker discovery and validation to support therapeutics development for neurodegenerative diseases
Topic 4: Optimal treatment for patients with solid tumours in Europe through artificial intelligence
Topic 5 Shortening the path to rare disease diagnosis by using new born genetic screening and digital technologies
Topic 6: Behavioural model of factors affecting patient adherence

Programme:

Innovative Medicines Initiative (IMI2)

Funder:

European Commission and European Federation of Pharmaceutical Industries and Associations (EFPIA)

Funding rate:

95 MLN

Who can participate:

H2020 participation rules:
a) at least three legal entities shall participate in an action;
b) three legal entities shall each be established in a different Member State or associated country;
c) the three legal entities referred to in point (b) shall be independent of each other.

Partenariato: Required

Status: Open

Topic:
Topic 1: Returning clinical trial data to study participants within a GDPR compliant and approved ethical framework Topic 2: Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance Topic 3: A platform for accelerating biomarker discovery and validation to support therapeutics development for neurodegenerative diseases Topic 4: Optimal treatment for patients with solid tumours in Europe through artificial intelligence Topic 5 Shortening the path to rare disease diagnosis by using new born genetic screening and digital technologies Topic 6: Behavioural model of factors affecting patient adherence

Who can participate:
H2020 participation rules: a) at least three legal entities shall participate in an action; b) three legal entities shall each be established in a different Member State or associated country; c) the three legal entities referred to in point (b) shall be independent of each other.

Programme:
Innovative Medicines Initiative (IMI2)

Consortium: Required

Status: Open

Total budget:
95 MLN

Funding rate: